KURA ONCOLOGY INC's ticker is KURA and the CUSIP is 50127T109. A total of 134 filers reported holding KURA ONCOLOGY INC in Q2 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $10,425,000 | +483.1% | 500,000 | +178.2% | 2.19% | +1069.5% |
| Q1 2020 | $1,788,000 | -84.8% | 179,700 | -79.0% | 0.19% | -81.7% |
| Q4 2019 | $11,739,000 | -74.9% | 853,777 | -72.3% | 1.02% | -76.2% |
| Q3 2019 | $46,815,000 | -99.9% | 3,086,053 | +1.3% | 4.30% | -35.5% |
| Q2 2019 | $60,011,000,000 | +136655.4% | 3,047,800 | +15.2% | 6.66% | +53.4% |
| Q1 2019 | $43,882,000 | +12.9% | 2,645,100 | -4.5% | 4.34% | -11.6% |
| Q4 2018 | $38,884,000 | +4.9% | 2,769,527 | +30.7% | 4.92% | -15.0% |
| Q3 2018 | $37,084,000 | -22.4% | 2,119,106 | -19.3% | 5.78% | -12.8% |
| Q2 2018 | $47,813,000 | -99.9% | 2,627,110 | +10.3% | 6.63% | -0.0% |
| Q1 2018 | $44,641,000,000 | +132689.0% | 2,380,846 | +8.4% | 6.63% | +15.6% |
| Q4 2017 | $33,618,000 | +28.4% | 2,197,283 | +25.5% | 5.74% | +12.6% |
| Q3 2017 | $26,176,000 | – | 1,750,887 | – | 5.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,849,947 | $16,871,517 | 9.37% |
| Prosight Management, LP | 1,932,456 | $17,623,999 | 5.58% |
| ACUTA CAPITAL PARTNERS, LLC | 702,093 | $6,403,088 | 4.29% |
| ALETHEA CAPITAL MANAGEMENT, LLC | 350,445 | $3,196,058 | 3.93% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,335,845 | $66,902,906 | 3.62% |
| Affinity Asset Advisors, LLC | 856,535 | $7,811,599 | 2.20% |
| TCG Crossover Management, LLC | 1,423,642 | $12,983,615 | 1.91% |
| EcoR1 Capital, LLC | 5,806,871 | $52,958,664 | 1.79% |
| BVF INC/IL | 6,730,983 | $61,386,565 | 1.66% |
| DAFNA Capital Management LLC | 550,784 | $5,023,150 | 1.56% |